Novo’s main shareholder pushes out more than half of company’s board

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Novo Nordisk’s largest investor said Tuesday it wants to replace more than half of the drugmaker’s board, calling an extraordinary general meeting of shareholders in November to install a handpicked slate of candidates. The election of new candidates is necessary because the current board was “too slow in recognizing” changes in the obesity drug ...